Inicio
Autor Fabián Juliao Baños
|
Comentario :
Médico Internista Gastroenterólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (44)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaDysplasia and Colorectal Cancer Surveillance in Ulcerative Colitis Patients in Latin America: Real-World Data / Parra Izquierdo, Viviana ; Otero Regino, William ; Fabián Juliao Baños ; Frías Ordoñez, Juan Sebastián ; Ibañez Pinilla, Edgar ; Gil Parada, Fabio Leonel ; Marulanda Fernández, Hernando ; Otero Parra, Lina ; Otero Ramos, Elder ; Puentes Manosalva, Fabian Eduardo ; Guzmán Rojas, Gerardo Andrés ; Ernest Suarez, Kenneth ; Villa Ovalles, Keyla ; Paredes Mendez, Juan Eloy ; Jara Alba, María Luisa ; Andrade Zamora, David ; Ardila Báez, Manuel Alonso ; Floréz Sarmiento, Cristian ; Veitia, Guillermo ; Sánchez, Abel ; Arango Molano, Lazaro Antonio ; Fluxa, Fernando ; Freitas Queiroz, Natália Sousa ; Serrano, Mariastella
Título : Dysplasia and Colorectal Cancer Surveillance in Ulcerative Colitis Patients in Latin America: Real-World Data Tipo de documento : documento electrónico Autores : Parra Izquierdo, Viviana, Autor ; Otero Regino, William, Autor ; Fabián Juliao Baños, Autor ; Frías Ordoñez, Juan Sebastián, Autor ; Ibañez Pinilla, Edgar, Autor ; Gil Parada, Fabio Leonel, Autor ; Marulanda Fernández, Hernando, Autor ; Otero Parra, Lina, Autor ; Otero Ramos, Elder, Autor ; Puentes Manosalva, Fabian Eduardo, Autor ; Guzmán Rojas, Gerardo Andrés, Autor ; Ernest Suarez, Kenneth, Autor ; Villa Ovalles, Keyla, Autor ; Paredes Mendez, Juan Eloy, Autor ; Jara Alba, María Luisa, Autor ; Andrade Zamora, David, Autor ; Ardila Báez, Manuel Alonso, Autor ; Floréz Sarmiento, Cristian, Autor ; Veitia, Guillermo, Autor ; Sánchez, Abel, Autor ; Arango Molano, Lazaro Antonio, Autor ; Fluxa, Fernando, Autor ; Freitas Queiroz, Natália Sousa, Autor ; Serrano, Mariastella, Autor Fecha de publicación : 2025 Títulos uniformes : Crohn's and Colitis 360 Idioma : Inglés (eng) Palabras clave : (MeSH): inflammatory bowel diseases; colitis; colonic neoplasms; colonoscopy; prognosis; ulcerative Resumen : Background: The prevalence of colorectal cancer (CRC) in patients with ulcerative colitis (UC) is higher than in the general population, in Latin America there is a progressive increase of UC, and information about CRC screening in inflammatory bowel disease (IBD) is scarce. The aim of this study was to analyze the findings of endoscopic surveillance of CRC in patients with IBD according to available technology. Methods: Multicenter, cross-sectional, analytical study conducted in Latin American countries, in patients with UC, predominantly with more than 8 years of diagnosis and different degrees of disease activity. Surveillance colonoscopies were performed according to available technology. Risk factors for dysplasia detection were analyzed. Results: One hundred and forty-four patients, 55.5% women, mean age 47.3 (range 17.1 to 90; SD 15.64) years and mean duration of disease 12.71 (range 0.64 to 57.13; SD 8.08) years. Forty-nine lesions were identified, 18 corresponded to dysplasia. The detection rate of dysplasia per lesion and per procedure was 36.7% and 12.5%, respectively. By logistic regression analysis, the duration of disease (OR 1.12;95%CI:1.047 to 1.215, P = .002) and the presence of post-inflammatory polyps (OR 3.4;95%CI:1.11 to 10.36, P = .031) were risk factors for higher detection of dysplasia. Digital chromoendoscopy was associated with greater detection of dysplasia (OR 4.99, 95%CI: 1.092 to 22.864, P = .038). Conclusions: In our region, the duration of disease and the presence of post-inflammatory polyps were the factors with the highest association for dysplasia detection, and digital chromoendoscopy with directed biopsies was the technique of choice. The implementation of a specific surveillance program in colonoscopy in IBD is an effective strategy to achieve high detection rates. © 2025 The Author(s). Mención de responsabilidad : Parra-Izquierdo, Viviana, Otero-Regino, William, Juliao-Baños, Fabian, Frías-Ordoñez, Juan Sebastián, Ibañez-Pinilla, Edgar, Gil-Parada, Fabio Leonel, Marulanda-Fernández, Hernando, Otero-Parra, Lina, Otero-Ramos, Elder, Puentes-Manosalva, Fabian Eduardo, Guzmán Rojas, Gerardo Andres, Ernest-Suárez, Kenneth, Villa-Ovalles, Keyla, Paredes-Mendez, Juan Eloy, Jara-Alba, María Luisa, Andrade-Zamora, David, Ardila-Báez, Manuel Alonso, Flórez-Sarmiento, Cristian, Veitia, Guillermo, Sánchez, Abel, Arango-Molano, Lazaro Antonio, Fluxa, Fernando, Freitas Queiroz, Natália Sousa, Serrano, Mariastella Referencia : Crohns Colitis 360 . 2025 Jan 14;7(1):otae081 DOI (Digital Object Identifier) : 10.1093/crocol/otae081 PMID : 39834355 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39834355/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Dysplasia and Colorectal Cancer Surveillance in Ulcerative Colitis Patients in Latin America: Real-World Data [documento electrónico] / Parra Izquierdo, Viviana, Autor ; Otero Regino, William, Autor ; Fabián Juliao Baños, Autor ; Frías Ordoñez, Juan Sebastián, Autor ; Ibañez Pinilla, Edgar, Autor ; Gil Parada, Fabio Leonel, Autor ; Marulanda Fernández, Hernando, Autor ; Otero Parra, Lina, Autor ; Otero Ramos, Elder, Autor ; Puentes Manosalva, Fabian Eduardo, Autor ; Guzmán Rojas, Gerardo Andrés, Autor ; Ernest Suarez, Kenneth, Autor ; Villa Ovalles, Keyla, Autor ; Paredes Mendez, Juan Eloy, Autor ; Jara Alba, María Luisa, Autor ; Andrade Zamora, David, Autor ; Ardila Báez, Manuel Alonso, Autor ; Floréz Sarmiento, Cristian, Autor ; Veitia, Guillermo, Autor ; Sánchez, Abel, Autor ; Arango Molano, Lazaro Antonio, Autor ; Fluxa, Fernando, Autor ; Freitas Queiroz, Natália Sousa, Autor ; Serrano, Mariastella, Autor . - 2025.
Obra : Crohn's and Colitis 360
Idioma : Inglés (eng)
Palabras clave : (MeSH): inflammatory bowel diseases; colitis; colonic neoplasms; colonoscopy; prognosis; ulcerative Resumen : Background: The prevalence of colorectal cancer (CRC) in patients with ulcerative colitis (UC) is higher than in the general population, in Latin America there is a progressive increase of UC, and information about CRC screening in inflammatory bowel disease (IBD) is scarce. The aim of this study was to analyze the findings of endoscopic surveillance of CRC in patients with IBD according to available technology. Methods: Multicenter, cross-sectional, analytical study conducted in Latin American countries, in patients with UC, predominantly with more than 8 years of diagnosis and different degrees of disease activity. Surveillance colonoscopies were performed according to available technology. Risk factors for dysplasia detection were analyzed. Results: One hundred and forty-four patients, 55.5% women, mean age 47.3 (range 17.1 to 90; SD 15.64) years and mean duration of disease 12.71 (range 0.64 to 57.13; SD 8.08) years. Forty-nine lesions were identified, 18 corresponded to dysplasia. The detection rate of dysplasia per lesion and per procedure was 36.7% and 12.5%, respectively. By logistic regression analysis, the duration of disease (OR 1.12;95%CI:1.047 to 1.215, P = .002) and the presence of post-inflammatory polyps (OR 3.4;95%CI:1.11 to 10.36, P = .031) were risk factors for higher detection of dysplasia. Digital chromoendoscopy was associated with greater detection of dysplasia (OR 4.99, 95%CI: 1.092 to 22.864, P = .038). Conclusions: In our region, the duration of disease and the presence of post-inflammatory polyps were the factors with the highest association for dysplasia detection, and digital chromoendoscopy with directed biopsies was the technique of choice. The implementation of a specific surveillance program in colonoscopy in IBD is an effective strategy to achieve high detection rates. © 2025 The Author(s). Mención de responsabilidad : Parra-Izquierdo, Viviana, Otero-Regino, William, Juliao-Baños, Fabian, Frías-Ordoñez, Juan Sebastián, Ibañez-Pinilla, Edgar, Gil-Parada, Fabio Leonel, Marulanda-Fernández, Hernando, Otero-Parra, Lina, Otero-Ramos, Elder, Puentes-Manosalva, Fabian Eduardo, Guzmán Rojas, Gerardo Andres, Ernest-Suárez, Kenneth, Villa-Ovalles, Keyla, Paredes-Mendez, Juan Eloy, Jara-Alba, María Luisa, Andrade-Zamora, David, Ardila-Báez, Manuel Alonso, Flórez-Sarmiento, Cristian, Veitia, Guillermo, Sánchez, Abel, Arango-Molano, Lazaro Antonio, Fluxa, Fernando, Freitas Queiroz, Natália Sousa, Serrano, Mariastella Referencia : Crohns Colitis 360 . 2025 Jan 14;7(1):otae081 DOI (Digital Object Identifier) : 10.1093/crocol/otae081 PMID : 39834355 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39834355/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002320 AC-2025-003 Archivo digital Producción Científica Artículos científicos Disponible
Título : P1261 Reproductive Health Outcomes in Colombian Women with Inflammatory Bowel Disease: A Multicenter Cohort Study on Pregnancy, Fertility, and Disease Impact (REINFORCE Study) Tipo de documento : documento electrónico Autores : Osorio Castrillón, Laura Marcela, Autor ; Fabián Juliao Baños, Autor ; Parra Izquierdo, Viviana, Autor ; Frías Ordoñez, Juan Sebastián, Autor Fecha de publicación : 2025 Títulos uniformes : Journal of Crohn's and Colitis Idioma : Inglés (eng) Resumen : Background: The impact of Inflammatory Bowel Disease (IBD) on women's health, particularly in relation to reproductive health, remains an underexplored area in Latin American populations. This study aims to assess the effects of IBD on women's reproductive health, including pregnancy outcomes, fertility, and related complications, within a cohort of Colombian women. Methods: Observational, multicenter and descriptive study involving adult and pediatric patients from two IBD Centers in different cities in Colombia. The study focused on evaluating aspects of sexual and reproductive health in women with IBD, with detailed data collection on pregnancy, fertility, childbirth, and cancer screening Results: Out of a total of 121 women with IBD, 63.6% (77/121 patients) were in reproductive age (15–44 years according to World Health Organization) (Table 1), the mean age was 33.2 years (range: 17.2–44.8 years, SD: 8), with a mean age at diagnosis of 28 years (range: 9.3–45.1 years, SD: 8.8) and a disease duration of 5.2 years (range: 0.3–21.9 years, SD: 4.7). UC was more prevalent in this group (71.4%). Most women had low rates of smoking, hospitalization, and surgical interventions for IBD, and pregnancy-related complications were generally rare. The majority of births were vaginal deliveries, and breastfeeding beyond 6 months was common, suggesting protective effects against IBD risk in offspring. Notably, while HPV vaccination rates were low, the prevalence of cervical cancer was also low. Family planning was reported by 48% of participants, and 1% required assisted reproductive technologies. Statistical analysis showed no significant association between age and pregnancy complications across age groups. However, UC was significantly associated with a higher risk of pregnancy complications (OR 5.5; 95% CI: 1.9–14.9; p=0.0001), and Crohn's disease (CD) also showed a trend toward increased risk (OR 4.6; 95% CI : 0.2–20.4; p=0.00002). Previous history of hospitalization due to disease activity, surgery, and the use of biological therapy was associated with an increased risk of pregnancy complications when it occurred (OR 1.97; 95% CI: 1.6–2.5; p= 0.07 for hospitalization, OR 12.12; 95% CI: 4.2–27.8; p=0.03 for surgery, OR 5.2; 95% CI: 1.64-13.1 ;p=0.00001). Conclusion: This study underscores the significant impact of IBD on reproductive health in Colombian women, similar to trends in other populations. It emphasizes the importance of effective disease management before conception, given that the use of biological therapies that usually are associated with more severe disease, ongoing disease activity, and prior surgical interventions are risk factors for increased pregnancy complications. Mención de responsabilidad : V Parra Izquierdo , L Osorio-Castrillon , F Juliao-Baños , J Frías-Ordoñez Referencia : Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i2282–i2283, DOI (Digital Object Identifier) : 10.1093/ecco-jcc/jjae190.1435 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i2282/7972126 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis P1261 Reproductive Health Outcomes in Colombian Women with Inflammatory Bowel Disease: A Multicenter Cohort Study on Pregnancy, Fertility, and Disease Impact (REINFORCE Study) [documento electrónico] / Osorio Castrillón, Laura Marcela, Autor ; Fabián Juliao Baños, Autor ; Parra Izquierdo, Viviana, Autor ; Frías Ordoñez, Juan Sebastián, Autor . - 2025.
Obra : Journal of Crohn's and Colitis
Idioma : Inglés (eng)
Resumen : Background: The impact of Inflammatory Bowel Disease (IBD) on women's health, particularly in relation to reproductive health, remains an underexplored area in Latin American populations. This study aims to assess the effects of IBD on women's reproductive health, including pregnancy outcomes, fertility, and related complications, within a cohort of Colombian women. Methods: Observational, multicenter and descriptive study involving adult and pediatric patients from two IBD Centers in different cities in Colombia. The study focused on evaluating aspects of sexual and reproductive health in women with IBD, with detailed data collection on pregnancy, fertility, childbirth, and cancer screening Results: Out of a total of 121 women with IBD, 63.6% (77/121 patients) were in reproductive age (15–44 years according to World Health Organization) (Table 1), the mean age was 33.2 years (range: 17.2–44.8 years, SD: 8), with a mean age at diagnosis of 28 years (range: 9.3–45.1 years, SD: 8.8) and a disease duration of 5.2 years (range: 0.3–21.9 years, SD: 4.7). UC was more prevalent in this group (71.4%). Most women had low rates of smoking, hospitalization, and surgical interventions for IBD, and pregnancy-related complications were generally rare. The majority of births were vaginal deliveries, and breastfeeding beyond 6 months was common, suggesting protective effects against IBD risk in offspring. Notably, while HPV vaccination rates were low, the prevalence of cervical cancer was also low. Family planning was reported by 48% of participants, and 1% required assisted reproductive technologies. Statistical analysis showed no significant association between age and pregnancy complications across age groups. However, UC was significantly associated with a higher risk of pregnancy complications (OR 5.5; 95% CI: 1.9–14.9; p=0.0001), and Crohn's disease (CD) also showed a trend toward increased risk (OR 4.6; 95% CI : 0.2–20.4; p=0.00002). Previous history of hospitalization due to disease activity, surgery, and the use of biological therapy was associated with an increased risk of pregnancy complications when it occurred (OR 1.97; 95% CI: 1.6–2.5; p= 0.07 for hospitalization, OR 12.12; 95% CI: 4.2–27.8; p=0.03 for surgery, OR 5.2; 95% CI: 1.64-13.1 ;p=0.00001). Conclusion: This study underscores the significant impact of IBD on reproductive health in Colombian women, similar to trends in other populations. It emphasizes the importance of effective disease management before conception, given that the use of biological therapies that usually are associated with more severe disease, ongoing disease activity, and prior surgical interventions are risk factors for increased pregnancy complications. Mención de responsabilidad : V Parra Izquierdo , L Osorio-Castrillon , F Juliao-Baños , J Frías-Ordoñez Referencia : Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i2282–i2283, DOI (Digital Object Identifier) : 10.1093/ecco-jcc/jjae190.1435 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i2282/7972126 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002372 AC-2025-055 Archivo digital Producción Científica Artículos científicos Disponible
Título : Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Autor ; Parra Izquierdo, Viviana, Autor ; Frías Ordoñez, Juan Sebastián, Autor ; Floréz Sarmiento, Cristian, Autor Fecha de publicación : 2024 Títulos uniformes : Gastroenterología y Hepatología Idioma : Español (spa) Palabras clave : Colitis ulcerosa; Disease management; Enfermedades inflamatorias del intestino; Inflammatory bowel diseases; Inhibidores de las quinasas janus; Janus kinase inhibitors; Manejo de la enfermedad; Terapéutica; Therapeutics; Tofacitinib; Ulcerative colitis. Resumen : Introduction: Tofacitinib is indicated in patients with moderate to severe ulcerative colitis (UC); however, given its rapid onset of action, it may constitute an alternative in patients with hospitalized severe acute UC. There are few data on this indication in the literature. The aim of this study was to describe the efficacy and safety of tofacitinib in the management of patients with hospitalized UC, as well as its clinical characteristics and other treatment patterns. Materials and methods: Descriptive observational study of adults and children with CUAG treated with tofacitinib between June 2019 and December 2022 in Colombia. Sociodemographic and clinical variables were collected, therapeutic response was evaluated in different periods of time and descriptive analysis of quantitative and qualitative variables was performed. Results: Six patients (five adults and one pediatric), mean age 33.2 (SD: 8.5) years, with CUAG. Symptom remission was obtained in 100% of patients at day 7 after tofacitinib initiation. In three patients information was obtained beyond 6 months, with 100% clinical, biochemical, and endoscopic remission and without requiring colectomy. In the case of the pediatric patient, symptom remission was achieved one week after starting tofacitinib, remaining in clinical, biochemical and endoscopic remission beyond 6 months. No serious adverse events were reported in any of the cases. Conclusions: Tofacitinib represents a rescue therapeutic alternative in CUAG, with rapid clinical response, adequate tolerance and less need for colectomy, being sustained for periods beyond 6 months. Mención de responsabilidad : Parra-Izquierdo, Viviana; Frías-Ordoñez, Juan Sebastián; Juliao-Baños, Fabián; Cuadros, Carlos; Romero Sanchez, Consuelo; Flórez-Sarmiento, Cristian Referencia : Gastroenterol Hepatol . 2024 Jun-Jul;47(6):582-590. DOI (Digital Object Identifier) : 10.1016/j.gastrohep.2023.10.003 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/37806342/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: A case series study [documento electrónico] / Fabián Juliao Baños, Autor ; Parra Izquierdo, Viviana, Autor ; Frías Ordoñez, Juan Sebastián, Autor ; Floréz Sarmiento, Cristian, Autor . - 2024.
Obra : Gastroenterología y Hepatología
Idioma : Español (spa)
Palabras clave : Colitis ulcerosa; Disease management; Enfermedades inflamatorias del intestino; Inflammatory bowel diseases; Inhibidores de las quinasas janus; Janus kinase inhibitors; Manejo de la enfermedad; Terapéutica; Therapeutics; Tofacitinib; Ulcerative colitis. Resumen : Introduction: Tofacitinib is indicated in patients with moderate to severe ulcerative colitis (UC); however, given its rapid onset of action, it may constitute an alternative in patients with hospitalized severe acute UC. There are few data on this indication in the literature. The aim of this study was to describe the efficacy and safety of tofacitinib in the management of patients with hospitalized UC, as well as its clinical characteristics and other treatment patterns. Materials and methods: Descriptive observational study of adults and children with CUAG treated with tofacitinib between June 2019 and December 2022 in Colombia. Sociodemographic and clinical variables were collected, therapeutic response was evaluated in different periods of time and descriptive analysis of quantitative and qualitative variables was performed. Results: Six patients (five adults and one pediatric), mean age 33.2 (SD: 8.5) years, with CUAG. Symptom remission was obtained in 100% of patients at day 7 after tofacitinib initiation. In three patients information was obtained beyond 6 months, with 100% clinical, biochemical, and endoscopic remission and without requiring colectomy. In the case of the pediatric patient, symptom remission was achieved one week after starting tofacitinib, remaining in clinical, biochemical and endoscopic remission beyond 6 months. No serious adverse events were reported in any of the cases. Conclusions: Tofacitinib represents a rescue therapeutic alternative in CUAG, with rapid clinical response, adequate tolerance and less need for colectomy, being sustained for periods beyond 6 months. Mención de responsabilidad : Parra-Izquierdo, Viviana; Frías-Ordoñez, Juan Sebastián; Juliao-Baños, Fabián; Cuadros, Carlos; Romero Sanchez, Consuelo; Flórez-Sarmiento, Cristian Referencia : Gastroenterol Hepatol . 2024 Jun-Jul;47(6):582-590. DOI (Digital Object Identifier) : 10.1016/j.gastrohep.2023.10.003 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/37806342/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002195 AC-2024-048 Archivo digital Producción Científica Artículos científicos Disponible
Título : Esofagitis eosinofílica: estado del arte en 2024 Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Autor ; Lúquez Mindiola, Adán, Autor Fecha de publicación : 2024 Títulos uniformes : Revista Colombiana de Gastroenterología Idioma : Español (spa) Palabras clave : Esofagitis eosinofilica Esofagitis Eosinofilia Diagnóstico Tratamiento Resumen : La esofagitis eosinofílica es una enfermedad inmune y alérgica que está incluida en los desórdenes gastrointestinales eosinofílicos primarios. La incidencia y prevalencia han aumentado en las últimas décadas, así como la conciencia de esta enfermedad entre los gastroenterólogos. Es más frecuente en hombres jóvenes con antecedentes atópicos. Los criterios diagnósticos incluyen síntomas e histología de esófago con un recuento ?15 eosinófilos/campo de alto poder o >60 eosinófilos/mm2, esta eosinofilia debe estar solo en el esófago y se deben descartar otras causas de eosinofilia. El tratamiento se basa en las 3 D: dieta, drogas y dilatación endoscópica. Se han aprobado nuevas terapias biológicas como dupilumab, y están en investigación novedosas estrategias terapéuticas para el manejo de esta enfermedad. Mención de responsabilidad : Adán Lúquez Mindiola, Fabián Juliao Baños Referencia : Revista Colombiana De Gastroenterologi?a, 39(4), 435–446. DOI (Digital Object Identifier) : 10.22516/25007440.1276 Derechos de uso : CC BY-NC-ND En línea : https://revistagastrocol.com/index.php/rcg/article/view/1276 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Esofagitis eosinofílica: estado del arte en 2024 [documento electrónico] / Fabián Juliao Baños, Autor ; Lúquez Mindiola, Adán, Autor . - 2024.
Obra : Revista Colombiana de Gastroenterología
Idioma : Español (spa)
Palabras clave : Esofagitis eosinofilica Esofagitis Eosinofilia Diagnóstico Tratamiento Resumen : La esofagitis eosinofílica es una enfermedad inmune y alérgica que está incluida en los desórdenes gastrointestinales eosinofílicos primarios. La incidencia y prevalencia han aumentado en las últimas décadas, así como la conciencia de esta enfermedad entre los gastroenterólogos. Es más frecuente en hombres jóvenes con antecedentes atópicos. Los criterios diagnósticos incluyen síntomas e histología de esófago con un recuento ?15 eosinófilos/campo de alto poder o >60 eosinófilos/mm2, esta eosinofilia debe estar solo en el esófago y se deben descartar otras causas de eosinofilia. El tratamiento se basa en las 3 D: dieta, drogas y dilatación endoscópica. Se han aprobado nuevas terapias biológicas como dupilumab, y están en investigación novedosas estrategias terapéuticas para el manejo de esta enfermedad. Mención de responsabilidad : Adán Lúquez Mindiola, Fabián Juliao Baños Referencia : Revista Colombiana De Gastroenterologi?a, 39(4), 435–446. DOI (Digital Object Identifier) : 10.22516/25007440.1276 Derechos de uso : CC BY-NC-ND En línea : https://revistagastrocol.com/index.php/rcg/article/view/1276 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002309 AC-2024-164 Archivo digital Producción Científica Artículos científicos Disponible
Título : The Global Evolution of In ammatory Bowel Disease across Four Epidemiologic Stages Tipo de documento : documento electrónico Autores : Fabián Juliao Baños, Autor Fecha de publicación : 2024 Títulos uniformes : Nature Communications Idioma : Inglés (eng) Resumen : During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD. Mención de responsabilidad : Lindsay Hracs # 1, Joseph W Windsor # 1, Julia Gorospe 1, Michael Cummings 2, Stephanie Coward 1, Michael J Buie 1, Joshua Quan 1, Quinn Goddard 1, Léa Caplan 1, Ante Markovinovi? 1, Tyler Williamson 2, Yvonne Abbey 3, Murdani Abdullah 4, Maria T Abreu 5 6, Vineet Ahuja 6 7, Raja Affendi Raja Ali 8, Mansour Altuwaijri 9, Domingo Balderramo 10, Rupa Banerjee 6 11, Eric I Benchimol 12 13 14 15, Charles N Bernstein 6 16, Eduard Brunet-Mas 17 18 19, Johan Burisch 6 20 21 22, Vui Heng Chong 23, Iris Dotan 6 24, Usha Dutta 25, Sara El Ouali 26 27, Angela Forbes 28, Anders Forss 29, Richard Gearry 6 28, Viet Hang Dao 30, Juanda Leo Hartono 31 32, Ida Hilmi 33, Phoebe Hodges 34 35, Gareth-Rhys Jones 36, Fabián Juliao-Baños 37, Jamilya Kaibullayeva 38 39, Paul Kelly 34 35, Taku Kobayashi 40 41, Paulo Gustavo Kotze 6 42, Peter L Lakatos 6 43 44, Charlie W Lees 45 46, Julajak Limsrivilai 47, Bobby Lo 20 21, Edward V Loftus Jr 6 48, Jonas F Ludvigsson 29 49, Joyce W Y Mak 50, YingLei Miao 51 52, K Referencia : Nature . 2025 Jun;642(8067):458-466 DOI (Digital Object Identifier) : 10.1038/s41586-025-08940-0. Epub 2025 Apr 30 PMID : 40307548 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40307548/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis The Global Evolution of In ammatory Bowel Disease across Four Epidemiologic Stages [documento electrónico] / Fabián Juliao Baños, Autor . - 2024.
Obra : Nature Communications
Idioma : Inglés (eng)
Resumen : During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD. Mención de responsabilidad : Lindsay Hracs # 1, Joseph W Windsor # 1, Julia Gorospe 1, Michael Cummings 2, Stephanie Coward 1, Michael J Buie 1, Joshua Quan 1, Quinn Goddard 1, Léa Caplan 1, Ante Markovinovi? 1, Tyler Williamson 2, Yvonne Abbey 3, Murdani Abdullah 4, Maria T Abreu 5 6, Vineet Ahuja 6 7, Raja Affendi Raja Ali 8, Mansour Altuwaijri 9, Domingo Balderramo 10, Rupa Banerjee 6 11, Eric I Benchimol 12 13 14 15, Charles N Bernstein 6 16, Eduard Brunet-Mas 17 18 19, Johan Burisch 6 20 21 22, Vui Heng Chong 23, Iris Dotan 6 24, Usha Dutta 25, Sara El Ouali 26 27, Angela Forbes 28, Anders Forss 29, Richard Gearry 6 28, Viet Hang Dao 30, Juanda Leo Hartono 31 32, Ida Hilmi 33, Phoebe Hodges 34 35, Gareth-Rhys Jones 36, Fabián Juliao-Baños 37, Jamilya Kaibullayeva 38 39, Paul Kelly 34 35, Taku Kobayashi 40 41, Paulo Gustavo Kotze 6 42, Peter L Lakatos 6 43 44, Charlie W Lees 45 46, Julajak Limsrivilai 47, Bobby Lo 20 21, Edward V Loftus Jr 6 48, Jonas F Ludvigsson 29 49, Joyce W Y Mak 50, YingLei Miao 51 52, K Referencia : Nature . 2025 Jun;642(8067):458-466 DOI (Digital Object Identifier) : 10.1038/s41586-025-08940-0. Epub 2025 Apr 30 PMID : 40307548 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/40307548/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002199 AC-2024-052 Archivo digital Producción Científica Artículos científicos Disponible
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
